Case report reveals exceptional survival with lorlatinib in an ALK-rearranged lung cancer patient, highlighting the importance of genetic testing to overcome targeted therapy resistance.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Szklener et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: